![]() ![]() The vaccine first became available in mid-February this year, with the Australian Technical Advisory Group on Immunisation (ATAGI) recommending a minimum gap of three weeks between doses. Most of the doses given so far have been given as the initial part a primary vaccination course. ‘These are expected side effects which were also seen in the clinical trials,’ the TGA report states. Reactions logged in the TGA database include paraesthesia, headache, chest pain, fatigue and dizziness.Īccording to AusVaxSafety, a National Centre for Immunisation Research and Surveillance-led initiative that runs more proactive surveillance of COVID-19 vaccines, the most common reactions have been fatigue, injection site reaction and headache. There have been no safety signals identified ‘based on the limited number of reports’ received so far, the TGA states. The report covers the initial stages of the rollout up until 6 March, in which around 35,500 doses of the protein-based vaccine had been administered, with the TGA receiving 78 reports of suspected adverse events. The first safety data on the rollout of the Novavax vaccine, the fourth to be approved for use in Australia, has been released in the latest Therapeutic Goods Administration (TGA) safety report. ![]() ![]() The Novavax vaccine is the most recent addition to the vaccine rollout in Australia. Early information on the administration of the Novavax vaccine in Australia is in line with clinical trials data, the TGA has reported. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |